News

The FDA has granted 510(k) clearance to a rapid, point-of-care test (RPS Adeno Detector Plus, Rapid Pathogen Screening Inc.) to diagnose adenoviral conjunctivitis.

Alcon Laboratories Inc., Alcon Research Ltd., and Kyowa Hakko Kirin Co. Ltd. have won a patent infringement lawsuit against Apotex, Inc. and Apotex Corp. in the U.S. District Court for the Southern District of Indiana.

David Beebe, PhD, FARVO, has been elected as the editor-in-chief of Investigative Ophthalmology & Visual Science (IOVS), the journal of the Association for Research in Vision and Ophthalmology (ARVO).

Four eye-care professionals will receive federal stimulus payments after attesting to meaningful use of the certified version of a proprietary electronic health record (EHR) system (OfficeMate/ExamWriter v10, Eyefinity).

The Vistakon Division of Johnson & Johnson Vision Care, Inc. has announced a new contest based on one of its contact lens brands. The Acuvue 1-Day Contest is open through June 30 to people aged 13 to 21 years. Five contestants will win a trip to Los Angeles to meet and be mentored by one of five top teen icons: musician Joe Jonas, actress Meaghan Martin, singer Charice, runner Allyson Felix, and actor Sterling Knight.

Eyenstein,? VSP Vision Care?s mobile eye-care clinic, arrived in Birmingham, AL, 3 days after deadly tornadoes raked the state. The mobile clinic, which is equipped with a comprehensive eye exam room, a full eyewear dispensary, and a lens finishing lab donated by Santinelli International, participated in disaster relief at Red Cross and Federal Emergency Management Agency shelters throughout Alabama.

Results of a randomized study comparing medication protocols for cataract surgery suggest that adding a corticosteroid to a regimen composed of twice-daily bromfenac 0.09% with a fourth-generation fluoroquinolone provides no extra benefit for controlling inflammation but increases the risk for IOP spikes on the first day after surgery.

Cataract removal using transversal phaco with a Venturi pump improved the followability of nuclear fragments and reduced chatter at the phaco tip compared with conventional longitudinal phaco with a peristatic pump.

Clear corneal microincisions of 2.2 and 1.8 mm produce similar low levels of surgically induced astigmatism after cataract extraction.

Although the head-to-head trial of bevacizumab and ranibizumab is being hailed as a landmark study, retina specialists are saying its results are unlikely to change practice patterns in the treatment of age-related macular degeneration.

Results of a study comparing fellow eyes undergoing femtosecond laser-assisted capsulotomy versus manual continuous curvilinear capsulorhexis show that the laser's initial advantage for predictably creating precisely sized and circular capsular openings is maintained during follow-up to 1 month after the procedure.

Optical coherence tomography may have a role in providing an honest assessment of visual potential for patients who have undergone surgery for visual loss due to compression.

Results of a study using optical coherence tomography to evaluate macular changes after cataract surgery indicate that laser refractive lens surgery with a proprietary femtosecond laser system is associated with less macular thickening and volume increase compared with traditional phacoemulsification.

The author takes on the critics of good ol' Rnnald McDonald.

The phacoemulsification performed equally well in a comparative study that also considered the different incision sizes.

Although the rate of glaucoma progression varies widely between patients, and prognostic factors to identify patients at higher risk for faster progression have been identified, the answer to the question of whether there are certain subgroups of patients who should be treated more aggressively than others is "no."

Descemet's membrane detachment and posterior wound gape, when they occur, develop very early after cataract surgery and decrease thereafter, while the incidence of posterior wound retraction emerges more slowly but is present in most eyes by 3 years postoperatively.

In patients with progressive optic nerve sheath meningiomas, fractionated stereotactic radiotherapy is the standard of care and prevents further vision loss.

The answer to the question of whether it is necessary to diagnose and treat pre-perimetric glaucoma is not a simple "yes" or "no."

The addition of intraoperative aberrometry to proper preoperative measurements and available clinical history improves refractive and functional outcomes after cataract surgery with accomudating IOL implantation in postLASIK patients.

The use of anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration has revolutionized the treatment of this disease, but concerns about the increased risk for elevated IOP with these agents continue to trouble ophthalmologists.

Accuracy of IOL power prediction using ray tracing is improving and approaching the performance of traditional regression formulae

Oraya Therapeutics Inc. completed enrollment of its INTREPID (I-Ray plus aNti-VEGF TREatment for Patients wIth Wet AMD) clinical trial April 15 in Europe, with 226 subjects.

The American Society of Ophthalmic Administrators (ASOA) has formed an affinity relationship with EyeCanHear LLC of Tampa, FL. EyeCanHear offers eye-care professionals tools to allow their practices to offer hearing-related services for patients.

Why would adults who have moderate to severe visual impairment not seek eye care? Cost or lack of insurance, and perception of no need, are the most common reasons, according to an analysis of data conducted by the Centers for Disease Control and Prevention (CDC).

Alimera Sciences Inc. resubmitted its new drug application, or NDA, for an investigational intravitreal insert containing fluocinolone acetonide (Iluvien) to the FDA May 12.

SynergEyes Inc. has added a new patient-focused video about astigmatism to two proprietary video libraries for eye-care professionals (3D-Eye Office and LUMA, Eyemaginations).

Re-profiling company iCo Therapeutics Inc. has entered into a consulting agreement with independent ophthalmic product development firm Ora Inc. in relation to the phase II clinical development of iCo-007.